Amplyx Pharmaceuticals Overview
- Founded
-
2006

- Status
-
Acquired/Merged
- Employees
-
26

- Latest Deal Type
-
M&A
Amplyx Pharmaceuticals General Information
Description
Developer of antifungal agents intended to treat invasive fungal infections. The company's agents use both intravenous and oral formulations to address the need for treatment in both the hospital setting and continued convenient treatment after discharge from the hospital, enabling patients undergoing chemotherapy and other immunosuppressive treatments, with compromised immune systems to get proper treatment for life-threatening invasive fungal infections due to candida, aspergillus, and rare molds.
Contact Information
Primary Office
- 12730 High Bluff Drive
- Suite 160
- San Diego, CA 92130
- United States
Amplyx Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Merger/Acquisition | 28-Apr-2021 | 00000 | Completed | Generating Revenue | ||
5. Secondary Transaction - Private | 00000 | Completed | Generating Revenue | |||
4. Later Stage VC (Series C) | 09-Jan-2020 | 000.00 | 00000 | 00000 | Completed | Generating Revenue |
3. Later Stage VC (Series B) | 27-Jun-2017 | 000.00 | 000.00 | 0000 | Completed | Generating Revenue |
2. Grant | 01-Jan-2017 | $11.3M | $2.3M | Completed | Generating Revenue | |
1. Early Stage VC (Series A) | 01-Jan-2011 | $2.3M | $2.3M | 000 | Completed | Generating Revenue |
Amplyx Pharmaceuticals Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C | 000,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series B | 000,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series A | 8,243,027 | $0.001000 | 8% | $0.27 | $0.27 | 1x | $0.27 | 2.04% |
Amplyx Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of antifungal agents intended to treat invasive fungal infections. The company's agents use both intravenous a
Drug Discovery
San Diego, CA
26
As of 2021
00000
000000&0
00000
Amplyx Pharmaceuticals Competitors (28)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Biosplice Therapeutics | Private Equity-Backed | San Diego, CA | 000 | 00000 | 0000000 0000 | 00000 |
000 | Venture Capital-Backed | Manchester, United Kingdom | 00 | 00000 | 0000000000 0 | 00000 |
00000 000000000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000000 | 00000 |
000000 00000000000 | Private Equity-Backed | Copenhagen, Denmark | 0000 | 000000000000 | ||
0000000 | Venture Capital-Backed | Wuppertal, Germany | 00 | 000.00 | 0000000000 | 000.00 |
Amplyx Pharmaceuticals Patents
Amplyx Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2021536446-A | Compounds and methods for treating fungal infections | Pending | 31-Aug-2018 | 0000000000 | |
EP-3843769-A1 | Compounds and methods for treating fungal infections | Pending | 31-Aug-2018 | 0000000000 | |
CA-3110860-A1 | Compounds and methods for treating fungal infections | Pending | 31-Aug-2018 | 0000000000 | |
AU-2019328599-A1 | Compounds and methods for treating fungal infections | Pending | 31-Aug-2018 | 0000000000 | |
US-20210290644-A1 | Compounds and methods for treating fungal infections | Pending | 31-Aug-2018 | A61K31/444 |
Amplyx Pharmaceuticals Board Members (13)
Name | Representing | Role | Since |
---|---|---|---|
Edward Mathers | Self | Board Member | 000 0000 |
Amplyx Pharmaceuticals Signals
Amplyx Pharmaceuticals Former Investors (22)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
3x5 Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Adage Capital Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
Ariel Savannah Angel Partners | Angel Group | Minority | 000 0000 | 000000 0 | |
Arix Bioscience | Venture Capital | Minority | 000 0000 | 000000 0 | |
BioMed Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |